Aclaris Therapts (ACRS) Stock Price, Quote & News

Company Profile

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JA...

Industry: Biotechnology

Sector: Healthcare

Phone: 484 324 7933

Website: www.aclaristx.com

Address:

701 Lee Road, Suite 103, Wayne, United States

Bionco Dec. 24 at 3:16 PM

$ACRS A successful Phase 2b trial of ATI-045 in AD would significantly de-risk both ATI-045 and the related ATI-052 program. These two assets alone could be worth $BILLIONS, even before accounting for the additional upside from the ITK inhibitor pipeline, which represents an even larger long-term value driver. For retail investors, what’s required is simply patience!

0 · Reply

Bionco Dec. 24 at 2:53 PM

$ACRS The Phase 2b data readout for ATI-045 will be a pivotal milestone for the company. If successful, it could unlock entirely new opportunities and transformative growth. With all other promising drug candidates, I'm targeting $50 per share within 2-3 yrs!

0 · Reply

Acan1219 Dec. 24 at 5:55 AM

$ACRS Latest Overnight Price! Let’s Gooo My Bull’s!💰💰💰

0 · Reply

OriginalTradeonrumor Dec. 23 at 6:11 PM

$ACRS so far so good!! Hoping folks here dove in this morning !!

0 · Reply

Bionco Dec. 23 at 6:03 PM

$ACRS Sadly, it is often the least informed speculators who end up losing their Hard-earned money in the stock market.

0 · Reply

OriginalTradeonrumor Dec. 23 at 2:49 PM

$ACRS I’m buying tons in upper 2.70’s low 2.80’s

0 · Reply

Banana0815 Dec. 23 at 2:39 PM

$ACRS whos selling? 🤔

0 · Reply

Bionco Dec. 23 at 1:06 PM

$ACRS Number of the clinical trial sites for AD has increased to 52 and the trial is progressing well as Dr. Walker mentioned at Jeffrey investors conference. We hope to surprise people next year! He knows the trial may have shown great efficacy in the pooled patients! He repeatedly stressed that every patient in the study had a verified AD(100% for sure), implying an unusually high placebo response rate is highly unlikely.

0 · Reply

Bionco Dec. 22 at 9:28 PM

$ACRS Hoping for the support of $3.03 to hold.✊

0 · Reply

Bionco Dec. 22 at 4:16 PM

$ACRS we are red while XBI is trading in deep green......

0 · Reply

Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)

Nov 25, 2025, 8:00 AM EST - 4 weeks ago

Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 6, 2025, 6:59 AM EST - 7 weeks ago

Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 29, 2025, 7:30 AM EDT - 2 months ago

Aclaris Therapeutics to Participate in Three November Healthcare Conferences

Oct 14, 2025, 5:46 PM EDT - 2 months ago

Aclaris Therapeutics, Inc. - Special Call

Sep 30, 2025, 7:00 AM EDT - 3 months ago

Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025

Sep 9, 2025, 7:00 AM EDT - 3 months ago

Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress

Aug 27, 2025, 8:00 AM EDT - 4 months ago

Aclaris Therapeutics to Participate in Two September Healthcare Conferences

Aug 7, 2025, 6:59 AM EDT - 5 months ago

Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 29, 2025, 4:01 PM EDT - 5 months ago

Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints

Jul 28, 2025, 8:45 AM EDT - 5 months ago

Aclaris Therapeutics Announces Leadership Transition

Jun 30, 2025, 9:31 AM EDT - 6 months ago

Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes

Jun 26, 2025, 4:01 PM EDT - 6 months ago

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference

Jun 23, 2025, 6:59 AM EDT - 6 months ago

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

May 28, 2025, 9:20 AM EDT - 7 months ago

Aclaris Therapeutics to Participate in Two June Healthcare Conferences

May 9, 2025, 7:00 AM EDT - 8 months ago

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series

May 8, 2025, 6:50 AM EDT - 8 months ago

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 29, 2025, 7:00 AM EDT - 8 months ago

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

Mar 4, 2025, 7:00 AM EST - 10 months ago

Aclaris Therapeutics to Participate in Two March Healthcare Conferences

Feb 12, 2025, 6:50 AM EST - 11 months ago

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

Jan 30, 2025, 4:01 PM EST - 11 months ago

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

Jan 6, 2025, 4:30 PM EST - 1 year ago

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Dec 23, 2024, 1:41 PM EST - 1 year ago

Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy

Nov 26, 2024, 4:30 PM EST - 1 year ago

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 3:27 PM EST - 1 year ago

Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments

Nov 18, 2024, 8:50 AM EST - 1 year ago

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

Nov 18, 2024, 8:10 AM EST - 1 year ago

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

Nov 18, 2024, 8:10 AM EST - 1 year ago

Aclaris Therapeutics Announces $80 Million Private Placement

Sep 17, 2024, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

Sep 10, 2024, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Jul 16, 2024, 4:01 PM EDT - 1 year ago

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million

Jun 25, 2024, 12:36 PM EDT - 1 year ago

Rheumatoid Arthritis Market and Epidemiology Forecast 2024-2034 Featuring Analysis of ATI-450 (Aclaris Therapeutics) and Olumiant/Baricitinib (Eli Lilly/Incyte)

Jun 6, 2024, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

May 8, 2024, 6:30 AM EDT - 1 year ago

American Clinical Research Services Announces Strategic Acquisition of Elixia

May 7, 2024, 9:44 PM EDT - 1 year ago

Aclaris Therapeutics, Inc. (ACRS) Q1 2024 Earnings Call Transcript

May 7, 2024, 4:01 PM EDT - 1 year ago

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Apr 23, 2024, 8:00 AM EDT - 1 year ago

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

Feb 27, 2024, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Jan 10, 2024, 7:00 AM EST - 2 years ago

Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis

Dec 19, 2023, 4:01 PM EST - 2 years ago

Aclaris Therapeutics Provides Corporate Update

Dec 5, 2023, 4:01 PM EST - 2 years ago

Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia

Nov 13, 2023, 7:19 AM EST - 2 years ago

Aclaris Therapeutics to stop development of rheumatoid arthritis drug

Nov 13, 2023, 7:00 AM EST - 2 years ago

Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update

Nov 6, 2023, 7:00 AM EST - 2 years ago

Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Oct 3, 2023, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)

Sep 28, 2023, 7:18 AM EDT - 2 years ago

Aclaris Therapeutics: The Many Lives Of This Biopharmaceutical Developer

Sep 20, 2023, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

Sep 18, 2023, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor

Aug 7, 2023, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

Jul 11, 2023, 7:31 PM EDT - 2 years ago

Aclaris Therapeutics: Q4 Of 2023 Catalyst Makes This A Must Watch

Bionco Dec. 24 at 3:16 PM

0 · Reply

Bionco Dec. 24 at 2:53 PM

0 · Reply

Acan1219 Dec. 24 at 5:55 AM

$ACRS Latest Overnight Price! Let’s Gooo My Bull’s!💰💰💰

0 · Reply

OriginalTradeonrumor Dec. 23 at 6:11 PM

$ACRS so far so good!! Hoping folks here dove in this morning !!

0 · Reply

Bionco Dec. 23 at 6:03 PM

$ACRS Sadly, it is often the least informed speculators who end up losing their Hard-earned money in the stock market.

0 · Reply

OriginalTradeonrumor Dec. 23 at 2:49 PM

$ACRS I’m buying tons in upper 2.70’s low 2.80’s

0 · Reply

Banana0815 Dec. 23 at 2:39 PM

$ACRS whos selling? 🤔

0 · Reply

Bionco Dec. 23 at 1:06 PM

0 · Reply

Bionco Dec. 22 at 9:28 PM

$ACRS Hoping for the support of $3.03 to hold.✊

0 · Reply

Bionco Dec. 22 at 4:16 PM

$ACRS we are red while XBI is trading in deep green......

0 · Reply

Bionco Dec. 22 at 11:02 AM

$ACRS The Phase 2 trials of TQC2731 in China for severe asthma and CRSwNP were officially completed in November 2025. Enrollment for the COPD trial also wrapped up this month! Back at the 2024 J.P. Morgan Healthcare Conference, Sino Biopharmaceuticals highlighted significant efficacy from surrogate endpoints of the trial for asthma. Can't wait for those full results in 2026—let's go!

1 · Reply

Acan1219 Dec. 21 at 6:02 AM

$ACRS The Successful Progression of ATI-045 is a Game Changer!💰💰💰Double Digit Stock Here My Bull’s!

0 · Reply

Acan1219 Dec. 20 at 3:12 AM

$ACRS Let’s Gooo my Bulls!

0 · Reply

Acan1219 Dec. 20 at 3:00 AM

$ACRS That’s Big!! A lot more eyes 👀 on ACRS Starting now! Double Digit Stock in coming!💰💰💰

1 · Reply

Bionco Dec. 19 at 9:38 PM

$ACRS good news👇👇

0 · Reply

Bionco Dec. 18 at 11:30 PM

$ACRS https://www.biospace.com/business/pharmas-write-big-m-a-checks-again-as-patent-urgency-seizes-c-suites

0 · Reply

Bionco Dec. 18 at 4:53 PM

$ACRS The ATI045 phase 2 trial for AD has been enrolling patients for 6 and half months. I guess the enrollment will be completed in Q12026.So far, no major safety issues have been reported. This is a very positive sign.

0 · Reply

OriginalTradeonrumor Dec. 17 at 5:09 PM

$ACRS this was a clear tech walk down to 3.10 area…if you want in …do it now!

0 · Reply

Bionco Dec. 16 at 11:56 PM

$ACRS someone just acquired 659k shares at the todays closing pricee

0 · Reply

Bionco Dec. 16 at 8:16 PM

$ACRS Dr Walker said we hope to surprise people next year 😁

0 · Reply

buymoremakemore Dec. 16 at 7:42 PM

$ACRS Alopecia Data from NKTR is unreliable in many people's eyes. I know we are not pursuing that any time soon. But at least less competition when we do. ATI-045 Phase 2b trial for AD might be one of the biggest paydays we ever get if the data is good. It will show that TSLP's with high potency, can be a lucrative solution to autoimmune diseases and tap into a multibillion dollar market. All of the big pharma and other companies dont have as efficacious and potent of a TSLP as we do. Sleeping giant.

1 · Reply

Bionco Dec. 16 at 3:15 PM

$ACRS up / down /up /down/up=consolidation followed by leg up😀

0 · Reply

Market Cap	314.20M
Revenue (ttm)	18.72M
Net Income (ttm)	-132.07M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-705.50%
Debt to Equity Ratio	0.00

Volume	440,300
Avg Vol	1,398,374
Day's Range	N/A - N/A
Shares Out	108.35M
Stochastic %K	41%
Beta	0.62
Analysts	Strong Sell
Price Target	$7.67